Category: Research
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards
To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program WASHINGTON, DC (December 1, 2022)— Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75…
-
Groups Award Two Grants for ALK-positive Lung Cancer Research
(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). “This is an…
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. Somewhat under the radar of our members is Moderna, Inc.’s multi-cancer clinical trial for their personalized mRNA vaccine that started in 2017. The trial is…
-
WE NEED YOUR INFO: Take part in our longitudinal survey of ALK+ Cancer Patients
More participants = more data = better research = more life!We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study conducted by researchers at University of Washington and paid for by ALK Positive Inc. All data is de-identified, and will inform oncologists, researchers, patients and…
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms of resistance so far. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL…
-
An Interview with Dr. Alice Shaw at ALKtALK, Feb. 2022
Dr. Alice Shaw, MD, PhD, Boston, MA Global Head of Translational Clinical Oncology at Novartis Attending physician, Center for Thoracic Cancers at Massachussets General Hospital Associate Professor of medicine at Harvard Medical School Transcript of ALKtALK, February 6, 2022 Introduction I am from Maryland originally. Then, after high school, I came up here to Boston,…
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the ALK-Positive Lung Cancer Research Award Program. This year, the patient oncogene group will potentially fund research projects totaling up to $1.5 million over two years—their…
-
$7.6M Gift Launches New Lung Cancer Research Initiative at University of Michigan’s Rogel Cancer Center
EDITOR’S NOTE: This is a reprint of a press release from the University of Michigan’s Rogel Cancer Center – this $7.6 million gift from Judith L. Tam and the Richard Tam Foundation may be the largest made to-date specifically for ALK-positive research. The direct link to the release is here: Increased understanding of the genetic…
-
Stronger Together: The Latest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients or caregivers themselves. The Board and Committees are all working together to improve the life expectancy and…
-
Understanding ALK structural data
“Know thy self, know thy enemy. A thousand battles, a thousand victories”; a quote by the famous Chinese historical figure Sun Tzu. Accordingly, scientists have been working hard at understanding the fundamentals of the ALK protein. Recently, a paper was published by a group of scientists in Belgium lead by Dr. Savvides, in which they described…
-
Sequencing treatment in ALK-positive cancer
The proverbial question, “what is my best treatment option?” is always on a patient’s mind. With the current treatment options available to us, ALKies, “what should we do?” comes up often. There are all the TKI options (Crizotinib, Ceritinib, Ensartinib, Alectinib, Brigatinib, and Lorlatinib), chemotherapy, radiation therapy and surgery (depending on your stage). By…